Navigation Links
REACH Registry Demonstrates That Multiple Arterial Disease,Locations Sharply Increase the Risk of Major CV Events in,Outpatients With Atherothrombosis

addition, the REACH registry is based in a real-life setting and seeks to increase overall understanding of atherothrombotic disease across several medical specialities (cardiology, neurology, internal medicine, vascular medicine and office-based primary care physicians), which allows for a more thorough assessment of the real-world burden of the disease.

The underlying cause of heart attack, stroke and PAD

Atherothrombosis occurs when a blood clot (thrombus) forms on a ruptured plaque (atheroma) in the wall of a blood vessel. Plaques consist of fatty acids and cholesterol, calcium and other materials.

The rupture of plaques and the subsequent development of a clot can cause partial or complete blockage of an artery in various parts of the body. When a vessel in the heart is partially or completely blocked by a clot the result can be a heart attack. In the brain, the same process can cause a stroke. Elsewhere in the body, this process can lead to reduction or blockage of blood flow in the arteries of the legs - PAD - a significant risk factor for heart attack or stroke.

Atherothrombosis is thus the common thread linking heart attack, stroke and peripheral arterial disease.

Notes to Editors:

REACH Registry

The REACH Registry is the first outpatient registry to characterize real-world event rates and treatment patterns in a broad spectrum of patients with atherothrombosis worldwide. The registry follows more than 60,000 patients over 4 years, involving 44 countries and 5,000 physician investigators. The REACH registry aims to improve the assessment and management of patients with a history of coronary artery disease (CAD), cerebrovascular disease (Stroke/TIA), peripheral arterial disease (PAD), and those with a combination of high risk factors

The REACH Registry is sponsored by Sanofi-Aventis, Britsol-Myers Squibb, and the Waksman Foundation (Tokyo, Japan), who assisted with the design and conduct of the study an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. ARRIVE Registry Analysis Identifies Predictors of Stent Thrombosis in Real-World Use of Drug-Eluting Stents
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
Post Your Comments:
(Date:7/29/2014)...  Express Scripts Holding Company (Nasdaq: ESRX ... Express Scripts stockholders of $515.2 million, or $0.67 per ... in Table 4, was $1.23 for the second quarter. ... serve our clients with scale, alignment and innovative solutions to ... outcomes of our members," stated George Paz, chairman and chief ...
(Date:7/29/2014)... , July 29, 2014 Pfenex Inc. (NYSE MKT: ... initial public offering of 8,333,333 shares of its common  stock ... All of the common stock was offered by Pfenex. In ... purchase up to 1,250,000 additional shares of common stock at ... are traded on the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... environmental radiation measurement and monitoring, outsourced medical physics services ... results for the fiscal third quarter 2014 after the ... The Company will host a conference call for ... Central Time (10 a.m. Eastern Time). Investors may access ...
Breaking Medicine Technology:Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31Pfenex Announces Closing of Initial Public Offering 2Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2
... 21, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... conferences: , Citi 2012 Global Healthcare Conference at ... , RBC Capital Markets, Healthcare Conference at 9:00 ... The sessions may be accessed through the Company,s ...
... 21, 2012  Acuo Technologies®, the leader in high-performance ... management and data migration, announces another year of ... achieved sales growth of over 90% from the ... from fiscal year end 2010.  The company signed ...
Cached Medicine Technology:Regeneron Announces February 2012 Investor Conference Presentations 2Acuo Technologies Announces Another Significant Growth Year in Sales to Further the Company's Market Leading Position 2
(Date:7/30/2014)... July 30, 2014 Pain Free Living ... sports bracelet for pain relief and improved performance. This ... titanium embedded in a silicone core that is sheathed ... Germanium and is embedded with scalar energy and Schumann ... “Pain Free Living has 12 years experience developing magnetic ...
(Date:7/29/2014)... 30, 2014 Recently, iFitDress.com, a well-known wedding ... satin bridal gowns . Aside from this, it has ... up to 68 percent off. All of its old and ... The company’s sales representative says excitedly, “We are pleased to ... new range, there are a lot of amazing items. It ...
(Date:7/29/2014)... a well-known online supplier, now allows worldwide clients to ... by providing graceful and sexy lingerie collection for August. ... sexy dresses , designed and developed by top ... price into consideration. Worry no more, because VogueQueen.com launches ... for all clients. , VogueQueen.com’s top designers sincerely ...
(Date:7/29/2014)... 2014)A diet rich in soy may help feminine hearts, ... today in Menopause , the journal of The ... to the diet of women in Asia, produces the ... similar to Asian migrants to North America, leads to ... and switching to soy from a Western diet after ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural Cure ... for any sufferer who is looking for an all-natural holistic ... the new program, Sarah Summer, says that her method is ... infection, too. Actually, this is the reason why she was ... , The Natural Cure for Yeast Infection review ...
Breaking Medicine News(10 mins):Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:Soy may help women's hearts if they start early 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2
... Key molecule identified by researchers , FRIDAY, Nov. ... to better treatments for bovine spongiform encephalopathy, better known ... Creutzfeldt Jakob disease. , A protein called Glypican-1 is ... from England now report, and understanding its role could ...
... exam may cut need for repeat scans, study suggests , ... to pinpoint the optimal timing of breast MRI scans in ... repeat scans, U.S. researchers say. , Previous studies have found ... 3 to14) of the menstrual cycle minimizes breast tissue enhancement. ...
... phase (days 3-14) of a normal menstrual cycle can ... premenopausal women with irregular cycles possibly reducing the ... and providing clearer images on which doctors make their ... issue of the American Journal of Roentgenology . ...
... Virginia Commonwealth University Massey Cancer Center and VCU Institute ... may play a pivotal role in two processes that ... metastasis. Scientists hope the finding could lead to an ... this gene resulting in inhibition of cancer growth. ...
... who have alcohol dependence problems drink significantly more than do ... found. The findings suggest that older problem drinkers may ... even more than younger abusers to achieve the effects they ... over age 60 who have alcohol dependence drink more than ...
... Nov. 20 HealthySkinPortal.com is pleased to announce that ... skin care providers in the HSP national network, is ... body contouring at its locations in Arizona and Illinois. ... are constantly being introduced. While some providers choose to ...
Cached Medicine News:Health News:Blood Test Could Boost Clarity of Breast MRI Results for Some 2Health News:Researchers identify role of gene in tumor development, growth and progression 2Health News:Older problem drinkers use more alcohol than do their younger counterparts 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 2Health News:Nu U Medspa to Offer Dysport, Zerona, SmartLipo at HealthySkinPortal.com 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: